Alizé Pharma 3 Aims to Become Leader in Treatment of Rare Endocrine and Metabolic Disease
Alizé Pharma 3, a biopharmaceutical company focused on developing therapies for rare diseases, including hypoparathyroidism, is making efforts to become a leading company focusing on rare endocrine and metabolic diseases. The company will establish operations in Europe and North America to achieve faster global regulatory approvals for leading candidate…